Palifermin and Hypertension

In this article, we will discuss Palifermin and Hypertension. So, let’s get started.

Palifermin and Hypertension

In a phase 1 placebo-controlled study in patients undergoing hematopoietic transplantation and receiving palifermin (3 doses pre-myelotoxic therapy and 3 doses post-transplant), the proportion of palifermin-treated patients reporting an
adverse event of hypertension in the 60- and 80-mcg/kg/day palifermin cohorts was
greater than in the placebo group (2/15 patients [13%], 2/14 [14%], and 2/23 [9%],
respectively). These events were transient and did not require treatment discontinuation in any patient. In an integrated analysis of adverse events across palifermin studies in the hematology transplant setting, hypertensive events were reported in 30/409 palifermin (7%) patients and 13/241 placebo (5%) patients.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.